Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from ...

Needham upgraded Collegium Pharmaceutical (COLL) to Buy from Hold with a $46 price target The analyst cites the company’s topline and ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, ...

The latest announcement is out from Collegium Pharmaceutical ( (COLL) ). Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with ...

Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $28.50 and last traded at $28.56, with a ...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...